CRISPR Stocks: How to Invest in Gene Editing…(And Is it a Good Idea)

Reporter: John Divine

Publication: U.S. News & World Report


Deadline: Jun 30, 2017 4:00 pm

A gene editing tool called CRISPR has shown remarkable promise in labs and many scientists think it can be used to effectively treat a wide range of diseases with genetic components like lung cancer, sickle cell, Huntington’s disease and others. Obviously such treatments would be huge commercial successes. There are currently several “pure play” CRISPR stocks on the market, companies developing CRISPR-based treatments or licensing the right to do so to others. These pure play companies, specifically, are EDIT, NTLA and CRSP. Are any or all of these stocks good long-term buying opportunities? Is this the best way for average investors to invest in and profit from the success of this potentially groundbreaking scientific process? Any thoughts on how an average investor can best wager on the success and proliferation of CRISPR, or on these 3 companies in particular, would be appreciated? Some comment on the risks and potential rewards involved would also be helpful.

Read Article: